Ignite Creation Date:
2024-05-05 @ 4:38 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00284336
Status:
COMPLETED
Last Update Posted:
2014-12-09
First Post:
2005-12-23
Brief Title:
Caelyx Adjuvant in Elderly Breast Cancer
Sponsor:
Universitaire Ziekenhuizen KU Leuven
Organization:
Universitaire Ziekenhuizen KU Leuven
Study Overview
Official Title:
An Open Label Phase II Trial to Investigate the Cardiac Effects of Pegylated Liposomal Doxorubicine Caelyx in Elderly Breast Cancer Patients With New Imaging and Biochemical Techniques
Status:
COMPLETED
Status Verified Date:
2014-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open label Phase II study in elderly patients 65y or older with early breast cancer who are candidate for adjuvant chemotherapy A scheme with liposomal doxorubicin Caelyx and cyclophosphamide endoxan will be used The aim is to study the cardiac effects of liposomal doxorubicin with new non-invasive techniques ie strain rate imaging classical echocardiography and special blood tests measuring troponin I and BNP
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| S28720 UZ KUL | None | None | None |